The present invention relates to a DNA cassette for the expression of therapeutic genes namely platelet derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) in carrier cells for the treatment of for treatment of chronic wounds, ischemic diseases and local and systemic degenerative disorders. Th...

The present invention relates to a DNA cassette for the expression of therapeutic genes namely fibroblast growth factor ‘FGF-1’, hepatocyte growth factor ‘HGF’, epidermal growth factor ‘EGF’, fibroblast growth factor ‘FGF-7’, insulin like growth factor ‘IGF-1’, homing gene ‘CXCR4’, ‘luciferase’, interleukin ‘IL-10’,...

TITLE: COMPOSITIONS OF CONSTRUCTS OF MODIFIED DNA SEQUENCES CODING SPECIFIC PEPTIDES FOR VACCINE AGAINST COVID-19 AND METHOD OF PREPARATION OF ADENOVIRAL VACCINES THEREOF. ABSTRACT: The invention describes modified DNA constructs of SEQ ID-1 to 5, using modified plasmids as in SEQ ID- 8 to 15 to create two Adeno...

The present invention relates to a DNA cassette for the expression of therapeutic genes namely Chimeric Antigen Receptor and Co-stimulatory molecules, and suicide genes and luciferase and EGFR domain in carrier cells for the treatment of inflammatory, autoimmune, neurodegenerative diseases and local and systemic deg...

The present invention relates to a DNA cassette for the expression of therapeutic genes namely with genes ‘furin cleavable insulin’, ‘insulin like growth factor-1, ‘urocortin-3’, ‘urocortin-2’, ‘glucokinase’, ‘luciferase’, ‘cytosine deaminase’, ‘herpes simplex thymidine kinase’, and ‘EGFR truncated domain’ in target...

The present invention relates to a DNA cassette for the expression of therapeutic genes namely haemoglobin, cytosine deaminase, HSV-TK, luciferase, etc. in carrier cells for the treatment of thalassemia, sickle cell disease and or glucose 6 phosphatase deficiency. The said therapeutic genes can be expressed one at a...

The invention describes adenoviral therapeutic product built to express the modified DNA constructs of SEQ ID NO-1 to 5, using modified plasmids as in SEQ ID NO- 8 to 15 to create two Adenoviral therapeutic candidates as in SEQ ID NO-6 and SEQ ID NO -7, wherein SEQ ID NO-6 is an adenoviral genome with DNA construct ...